Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Summary

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Description

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage